Sun Pharmaceutical Industries Limited has informed the Exchange about Update on US FDA Halol Inspection
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The US FDA carried out a Good Manufacturing Practices (GMP) inspection at Sun Pharma's Halol facility in Gujarat from June 2 to June 13, 2025. At the end of the inspection, the FDA issued a Form-483 with 8 observations. This is a follow-up to the company's earlier update on Halol from December 16, 2022. A Form-483 lists conditions or practices that may violate FDA regulations, and the company will need to respond with corrective actions within the stipulated timeframe.
Form-483 observations are common in FDA inspections and not yet a warning letter or import alert, so the immediate business impact is limited. However, investors should watch for the company's response and any escalation, as the Halol plant is a key manufacturing facility supplying the US market.